Ketamine, the controlled drug best known as a horse tranquilizer or party supplement, has in the last four years become a boon to scores of severely depressed patients in Singapore. Since October 2020 ...

Pharmaceutical giant Johnson & Johnson (J&J) (NYSE:JNJ) has announced plans to acquire Intra-Cellular Therapies (NASDAQ:ITCI) ...

S&P Global Ratings placed Johnson & Johnson on CreditWatch with negative implications, citing its nearly $15 billion deal to acquire mental-illness drug developer Intra-Cellular Therapies.

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Johnson & Johnson is set to acquire Intra-Cellular Therapies for $14.6 billion. The deal includes Caplyta, a treatment for schizophrenia and bipolar depression, along with a pipeline focused on ...

Johnson & Johnson agreed to acquire Intra-Cellular Therapies Inc., a company focused on treatments for central nervous system ...

Republicans are poised to take control of the House of Representatives this month by the narrowest seat margin in nearly 100 ...

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

New Brunswick-based Johnson & Johnson and Bedminster-based Intra-Cellular Therapies, Inc. have entered into a definitive agreement ...